Changes in Body Mass Index with Longer-Term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE)

Emma M. Kileel, Carlos D. Malvestutto, Janet Lo, Kathleen V. Fitch, Carl J. Fichtenbaum, Judith A. Aberg, Markella V. Zanni, Esteban Martinez, Nwora Lance Okeke, Princy Kumar, Esau Joao, Sara H. Bares, Daniel Berrner, Marek Smieja, Jhoanna C. Roa, Sara McCallum, Pamela S. Douglas, Heather J. Ribaudo, Steven K. Grinspoon

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Over 2-years of follow-up, integrase strand transfer inhibitor (INSTI)-use was associated with weight gain among those on an INSTI <2 years at entry (+0.27 kg/m2/year; 95% confidence interval [CI],. 22 to. 33 vs +0.17 kg/m2/year; 95% CI,. 12 to. 23; P =. 01), but not those on an entry INSTI >2 years.

Original languageEnglish (US)
Pages (from-to)2010-2013
Number of pages4
JournalClinical Infectious Diseases
Volume76
Issue number11
DOIs
StatePublished - Jun 1 2023

Keywords

  • HIV
  • body mass index (BMI)
  • integrase strand transfer inhibitors (INSTIs)
  • weight

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Changes in Body Mass Index with Longer-Term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE)'. Together they form a unique fingerprint.

Cite this